TradingView’s own chart and price feed. The page’s numbers are end-of-day closes.
Data provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.
The numbers
fiscal 2025, as filed with the SEC · 66-metric EOD snapshot via Databento
Market cap$3.9B
EV / True FCF738.6x
Revenue$379.8M +13.8%
True FCF (ex-SBC)$5.1M +58.3%
Rule of 4024.3%
ROIC-13.1%
True FCF Yield0.1%
EPS, diluted$-0.40 −143.0%
Modern Valuation (EOD)
Market Cap$3.9B
Enterprise Value$3.8B
EV / True FCF738.62
EV / FCF94.79
EV / Gross Profit—
EV / EBIT—
EV / Sales9.98
P / E (GAAP)—
P / FCF96.44
P / Oper. CF91.77
P / Book12.73
Owner & Cash Yields
True FCF Yield0.1%
FCF Yield1.0%
Owner Earn. Yield-1.1%
Earnings Yield-0.6%
Shareholder Yield+1.4%
Buyback Yield2.3%
Dividend Yield—
Dividend / sh—
Payout Ratio—
FCF / sh$0.76
EPS (diluted)$-0.40
Compounder & Returns
Rule of 4024.3%
ROIC-13.1%
Cash ROIC (CROIC)16.9%
GP / Assets—
ROE-7.0%
ROA-5.2%
Gross Margin—
Oper. Margin-8.1%
Net Margin-5.6%
FCF Margin10.5%
True FCF Margin1.4%
Quality & Dilution
Cash Conversion—
Accrual Ratio−15.3%
SBC % of FCF87.2%
SBC % of Rev9.2%
Reinvest. Rate175%
Sales Growth Y/Y+13.8%
Sales 3Y CAGR+5.7%
EPS Growth Y/Y−143.0%
FCF Growth Y/Y+58.3%
FCF 3Y CAGR—
Share Change Y/Y−5.9%
Balance Sheet & Scale
Revenue (FY)$379.8M
Gross Profit (FY)—
Oper. Income (FY)$-30.8M
GAAP Net Income$-21.4M
True FCF (ex-SBC)$5.1M
Cash & Equiv$66.0M
Total Debt—
Net Cash (Debt)$66.0M
Net Cash % MCap+1.7%
Debt / FCF (yrs)0.0y
Current Ratio2.8652.54M sh
Price & Technicals (EOD)
Perf Week−8.29%
Perf Month+7.57%
Perf Quarter+58.42%
Perf Half Y+251.96%
Perf YTD+255.15%
SMA 20 Dist−4.01%$77.55
SMA 50 Dist+9.84%$67.77
SMA 100 Dist+36.18%$54.66
Window High−15.86%$88.47
Window Low+272.76%$19.97
RSI (14) · Vol50.096%v
Income Distribution & Cash Flow ConversionHow every dollar of CDNA revenue flows through cost of goods, operating expenses, taxes, GAAP net income, and dilution-adjusted free cash flow
Unlocked SEC EDGAR Accounting Statements (USD)All 3 statements · Common-size (% of Revenue / Assets) · YoY growth · Tap any core row to explain
Line Item (USD)
FY2021
FY2022
FY2023
FY2024
FY2025
YoY Δ
4Y CAGR
Trend
Income Statement
Revenue ▸
$296.4M
$321.8M
$280.3M
$333.8M
$379.8M
+13.8%
+6.4%
Cost of Revenue (COGS)
—
—
—
—
$45.5M
—
—
Research & Development (R&D)
$76.5M
$90.4M
$82.4M
$72.5M
$71.4M
−1.5%
−1.7%
Total Operating Expenses
$326.1M
$399.0M
$483.7M
$293.0M
$410.6M
+40.1%
+5.9%
Operating Income (EBIT) ▸
$-29.7M
$-77.2M
$-203.4M
$40.8M
$-30.8M
−175.5%
—
Income Tax Expense
$-1.4M
$379,000
$141,000
$310,000
$271,000
−12.6%
—
GAAP Net Income ▸
$-30.7M
$-76.6M
$-190.3M
$52.5M
$-21.4M
−140.6%
—
Diluted EPS ▸
$-0.59
$-1.44
$-3.54
$0.93
$-0.40
−143.0%
—
Diluted Shares
52.2M
53.3M
53.8M
56.6M
53.3M
−5.9%
+0.5%
Balance Sheet
Cash & Equivalents
$348.7M
$90.4M
$82.8M
$115.3M
$66.0M
−42.8%
−34.0%
Inventory
$17.2M
$19.2M
$19.5M
$19.5M
$26.7M
+36.9%
+11.6%
Total Current Assets
$433.4M
$387.8M
$313.7M
$351.8M
$257.1M
−26.9%
−12.2%
Total Assets
$566.6M
$543.0M
$466.8M
$491.1M
$413.2M
−15.8%
−7.6%
Total Current Liabilities
$77.3M
$76.0M
$78.1M
$89.4M
$89.8M
+0.5%
+3.8%
Total Debt (Short + Long Term)
$0
$0
$0
$0
$0
—
—
Total Liabilities
$100.7M
$112.1M
$205.5M
$112.6M
$110.1M
−2.2%
+2.3%
Stockholders' Equity
$465.9M
$430.9M
$261.3M
$378.4M
$303.1M
−19.9%
−10.2%
Net Cash / (Net Debt)
$348.7M
$90.4M
$82.8M
$115.3M
$66.0M
−42.8%
−34.0%
Invested Capital
$117.2M
$340.5M
$178.5M
$263.2M
$237.1M
−9.9%
+19.3%
Cash Flow & Capital Allocation
Operating Cash Flow (OCF) ▸
$-19.3M
$-25.2M
$-18.4M
$38.0M
$42.0M
+10.5%
—
Depreciation & Amortization (D&A)
$8.8M
$11.6M
$14.4M
$14.2M
$15.0M
+5.8%
+14.3%
Stock-Based Compensation (SBC)
$36.1M
$46.6M
$49.1M
$66.4M
$34.9M
−47.5%
−0.9%
Capital Expenditures (CapEx)
—
—
—
—
$2.0M
—
—
Free Cash Flow (FCF) ▸
—
—
—
—
$40.0M
—
—
True FCF (ex-SBC Owner Cash)
—
—
—
—
$5.1M
—
—
Share Repurchases (Buybacks)
$0
$642,000
$27.5M
$522,000
$87.8M
+16713.8%
—
Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.
On the Wire
what CDNA did at the next close after each story
No Wire story has named CDNA yet.
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.
What happened · big days
20 big days in a year, and what we hold on each
A big day is a close more than 5.97% from the one before, three times CDNA’s median day (1.99%). On 1 of the 20, its peer group moved the same way at least half as far. We show what we hold. We never name a cause.
every other trading daya big day, numbered in the list below±5.97%Hover a bar for its day. Click a big day to open it.
Shaded: since our stories began, Jun 10. Tap a bar for its day.
#DayCDNAWhat we hold that dayGroup (median of 4) · each
1 Nov 21, 2025+9.01%
Before our storiesgroup +2.1%, did not move with it
1Nov 21, 2025+9.01%
Before our stories
+2.1% did not move with itGH +5.1 · NTRA +2.3 · DGX +1.9 · LH +1.6
2 Dec 3, 2025+8.08%
Before our storiesgroup +0.3%, did not move with it
2Dec 3, 2025+8.08%
Before our stories
+0.3% did not move with itGH +2.0 · NTRA +0.7 · DGX +0.0 · LH −0.1
3 Jan 8, 2026−8.89%
Before our storiesgroup −0.7%, did not move with it
3Jan 8, 2026−8.89%
Before our stories
−0.7% did not move with itNTRA −5.8 · GH −1.1 · DGX −0.2 · LH +0.4
4 Jan 12, 2026+20.08%
Resultsgroup −0.0%, did not move with it
4Jan 12, 2026+20.08%
ResultsFirst close after the Jan 12 results filing
−0.0% did not move with itDGX +0.9 · NTRA +0.5 · LH −0.6 · GH −2.4
5 Feb 4, 2026−8.24%
Before our storiesgroup −2.3%, did not move with it
5Feb 4, 2026−8.24%
Before our stories
−2.3% did not move with itNTRA −9.7 · GH −6.1 · LH +1.4 · DGX +2.2
6 Feb 6, 2026+6.10%
Before our storiesgroup +1.3%, did not move with it
6Feb 6, 2026+6.10%
Before our stories
+1.3% did not move with itGH +3.5 · NTRA +3.0 · LH −0.4 · DGX −0.8
7 Apr 9, 2026−6.86%
Before our storiesgroup −2.1%, did not move with it
7Apr 9, 2026−6.86%
Before our stories
−2.1% did not move with itGH −6.1 · NTRA −3.7 · LH −0.5 · DGX −0.5
8 Apr 16, 2026+27.60%
Before our storiesgroup −0.1%, did not move with it
8Apr 16, 2026+27.60%
Before our stories
−0.1% did not move with itGH +1.0 · DGX +0.0 · LH −0.1 · NTRA −5.3
9 Jun 18, 2026+11.50%
Nothing on CDNAgroup +0.3%, did not move with it
9Jun 18, 2026+11.50%
Nothing on CDNANo CDNA story, brief or results filing in our record that day
+0.3% did not move with itNTRA +2.2 · GH +2.1 · DGX −1.4 · LH −1.4
10 Jun 24, 2026+8.00%
Nothing on CDNAgroup +3.9%, did not move with it
10Jun 24, 2026+8.00%
Nothing on CDNANo CDNA story, brief or results filing in our record that day
+3.9% did not move with itNTRA +10.7 · GH +4.7 · DGX +3.0 · LH +2.5
11 Jul 16, 2026+35.60%
Nothing on CDNAgroup +0.5%, did not move with it
11Jul 16, 2026+35.60%
Nothing on CDNANo CDNA story, brief or results filing in our record that day
+0.5% did not move with itDGX +3.8 · LH +3.7 · NTRA −2.7 · GH −4.9
12 Jul 30, 2026+7.60%
Nothing on CDNAgroup +4.2%, moved with CDNA
12Jul 30, 2026+7.60%
Nothing on CDNANo CDNA story, brief or results filing in our record that day
+4.2% moved with CDNANTRA +6.2 · GH +5.8 · LH +2.7 · DGX −0.4
13 Jul 31, 2026+14.72%
Resultsgroup −0.6%, did not move with it
13Jul 31, 2026+14.72%
ResultsFirst close after the Jul 30 results filing
−0.6% did not move with itGH +6.3 · DGX −0.6 · NTRA −0.7 · LH −2.0
14 Aug 3, 2026+9.47%
Nothing on CDNAgroup −0.5%, did not move with it
14Aug 3, 2026+9.47%
Nothing on CDNANo CDNA story, brief or results filing in our record that day
−0.5% did not move with itNTRA +1.0 · DGX −0.5 · LH −0.6 · GH −1.9
15 Aug 25, 2026+6.95%
Nothing on CDNAgroup +0.7%, did not move with it
15Aug 25, 2026+6.95%
Nothing on CDNANo CDNA story, brief or results filing in our record that day
+0.7% did not move with itNTRA +2.7 · GH +1.1 · DGX +0.3 · LH −0.5
16 Sep 24, 2026+13.00%
Nothing on CDNAgroup +1.6%, did not move with it
16Sep 24, 2026+13.00%
Nothing on CDNANo CDNA story, brief or results filing in our record that day
+1.6% did not move with itNTRA +4.6 · LH +1.6 · DGX +1.5 · GH +0.1
17 Oct 6, 2026−8.68%
Nothing on CDNAgroup −3.8%, did not move with it
17Oct 6, 2026−8.68%
Nothing on CDNANo CDNA story, brief or results filing in our record that day
−3.8% did not move with itGH −8.8 · NTRA −5.9 · DGX −1.6 · LH +1.0
18 Oct 30, 2026+22.22%
Resultsgroup −2.7%, did not move with it
18Oct 30, 2026+22.22%
ResultsFirst close after the Oct 29 results filing
−2.7% did not move with itDGX −0.4 · LH −1.8 · GH −3.5 · NTRA −5.0
19 Nov 5, 2026−11.10%
Nothing on CDNAgroup −4.1%, did not move with it
19Nov 5, 2026−11.10%
Nothing on CDNANo CDNA story, brief or results filing in our record that day
−4.1% did not move with itGH −9.0 · NTRA −7.0 · LH −1.2 · DGX −0.4
20 Nov 9, 2026+7.46%
Nothing on CDNAgroup +2.4%, did not move with it
20Nov 9, 2026+7.46%
Nothing on CDNANo CDNA story, brief or results filing in our record that day
+2.4% did not move with itGH +5.3 · NTRA +3.1 · DGX +1.6 · LH +1.4
A story on the same day is not a cause, and a group move is not proof either. Group: the median of NTRA, LH, DGX and GH that day, the largest companies in CDNA’s SEC industry; “moved with CDNA” means the same direction and at least half the size.
What’s next · results
Before the next report: what the first day after the last four did
Six trading days after each results filing (SEC 8-K, Item 2.02). CDNA reports after the close, so day 1 is the next close. Each time, day 6 ended on the same side as day 1.
Reported Feb 24, 2026
day 1−4.10%day 6−0.99%
Reported Apr 28, 2026
day 1−5.07%day 6−4.38%
Reported Jul 30, 2026
day 1+14.72%day 6+22.55%
Reported Oct 29, 2026
day 1+22.22%day 6+9.84%
Next report: expected late JanuaryEstimated from the dates of its last four results filings. Not announced. Since the Oct 29 report: +4.25%. Four reports is a small sample.
Each line is CDNA’s close against its close before the filing, on licensed end-of-day closes. What happened after each report, not a forecast; a move on the day is not a cause.
Same industry
CDNA against four same-industry peers, a year at 100
CDNA is up 4.3 times in a year. All four did less: Labcorp Holdings (+38.6%), Guardant Health (+35.9%), Quest Diagnostics (+34.0%) and Natera (+24.7%). Weekly closes, Nov 21, 2025 = 100, on a log scale so a 4.3-fold rise and a 24.7% rise both read honestly.
End-of-day closes (Databento EOD), the last close of each week. The four peers are the largest US-listed companies by market value in CDNA’s SEC industry (Services-Medical Laboratories) with a year of closes. It shows what the closes did; a move here is not a cause, a forecast or a call.